Introduction
Moxifloxacin-HCl (BAY 12-8039) is a new 8-methoxyquinolone with a broad sprectrum of antimicrobial activity against respiratory tract pathogens, including Grampositive and Gram-negative organisms, anaerobic bacteria and atypical respiratory tract pathogens. 1, 3 A dosage of 400 mg moxifloxacin, od, is currently under development. This dose showed very rapid bactericidal activity in animal models of typical and atypical respiratory tract infections [2] [3] [4] and showed favourable tissue kinetics (rapid penetration into the extravascular compartment and lung tissues). 5 Unlike some other quinolone antibiotics, moxifloxacin has no phototoxic potential. 6 In order to optimize dosing schedules and to answer questions related to exposure/side effect relationships, characterization of the basic pharmacokinetic properties of the drug formulations intended for treatment is a key issue. In a previous study it was shown that only phase 2 biotransformation is relevant in human metabolism. 7 Figure 1 illustrates the relevant metabolic pathway of the drug. This paper describes the results of a study in healthy volunteers comparing pharmacokinetics of iv and oral moxifloxacin after single-dose administration. Special attempts were made to quantify excretion of the drug as completely as possible in order to avoid a radiolabelling study in human volunteers.
Materials and methods

Study design
The pharmacokinetics of moxifloxacin (Bayer AG, Leverkusen, Germany) following single oral and iv dosages of 400 mg were investigated in a controlled, randomized, non-blind, two-way crossover study. Intravenous moxifloxacin was administered as a 1 h infusion and oral tablets were administered with 100 mL tap water at 8 a.m. under fasting conditions. There was a washout interval of at least 7 days between study days. On study days eating was not
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Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man The pharmacokinetics of moxifloxacin and its metabolites M1 (sulpho-compound) and M2 (acyl-glucuronide) were characterized in 12 healthy male volunteers in an open, randomized, crossover study. After an overnight fast the volunteers were given a single 400 mg dosage of moxifloxacin either as a tablet or a 1 h infusion with a washout phase of at least 1 week between the two treatments. Multiple plasma, faeces and urine samples were collected for the analysis of moxifloxacin and metabolites using validated HPLC with fluorescence detection. The AUC for both formulations was comparable with bioequivalence criteria fulfilled, with C max after oral treatment approximately 31% lower. Following oral administration, absorption was fast with low to medium variability (mean dissolution and absorption time 2.4 h). The absolute bioavailability was 86%. The excretion of moxifloxacin and its metabolites was quantified in a subset of eight subjects. More than 96% of the dose was recovered from urine and faeces after oral dosing, and >98% following iv administration of the drug. M1, which is strongly bound to plasma proteins (90%), was mainly eliminated into faeces (approximately 37-38% of the administered dose) and to a minor extent into urine (2.5% of the administered dose) by active tubular secretion. M2 (only 5% bound to plasma protein) was only found in urine, where it amounted to approximately 14% of the dose. Plasma concentrations of the metabolites were much lower than those of the parent compound. Moxifloxacin was well tolerated with few adverse events and no clinically relevant changes in laboratory values.
allowed up to 4 h after drug administration; drinking water was given ad libitum. The subjects were not permitted to take any medication from 2 weeks before the end of the study. Twelve young male Caucasians aged 23-41 years (mean 33 Ϯ 6 years) participated in this study. Their bodyweights ranged from 71-112 kg (mean 85 Ϯ 11 kg), their heights ranged from 172-197 cm (mean 182 Ϯ 7 cm) and their broca indices from 0.90-1.15 (mean 1.04 Ϯ 0.08). All subjects were healthy as assessed by physical examination, vital signs, ECG and laboratory tests including clinical chemistry, haematology and urinalysis up to 96 h post-dose. All participants gave their written informed consent. This study was conducted according to the provisions of legal guidelines and the Declaration of Helsinki 8 after the protocol was approved by the Ethics Committee of the NorthRhine Medical Council.
Blood sampling and additional procedures
Blood plasma samples (approximately 5 mL) for the determination of moxifloxacin and its major metabolites M1 and M2 ( Figure 1 For the mass balance investigation, faeces were collected quantitatively up to 6 days following drug administration in a sub-population of eight volunteers. After weighing, the faeces samples were homogenized in water by ultraturrax while cooling. From this slurry a representative sample was freeze-dried to yield a fine powder with constant weight. The powder was kept in polyethylene containers at -20°C before analysis.
Safety and tolerability
Tolerability and safety assessments, clinical chemistry, haematological tests and urinalysis, and the measurement of vital signs (blood pressure, heart rate) and ECG were included in the study. All data relating to drug safety were recorded throughout the study.
Drug and metabolite assays
Plasma samples were analysed for moxifloxacin and its metabolites by a specific and sensitive HPLC procedure with fluorescence detection 9 after deproteination and dilution with acetonitrile phosphate buffer (pH ϭ 4). For the determination of M1, chromatographic conditions were slightly adapted (acetonitrile was added to the mobile phase) to optimize chromatographic resolution. For the determination of M2, the plasma samples were subjected to enzymatic glucuronide cleavage by incubation with -glucuronidase (Sigma, Munich, Germany) for 4 h at 27°C in a water bath.
Faeces samples were freeze-dried to determine their dry weight. An aliquot (20-30 mg) was extracted with 2 mL of a mixture of acetonitrile and aqueous phosphate buffer (pH ϭ 2) (1:1 v/v) and analysed as described above for p l a s m a .
Following dilution using aqueous phosphate buffer (pH ϭ 4), analysis of urine was carried out by HPLC with fluorescence detection, as described above. All assays were fully validated according to European CPMP and FDA guidelines; the mean accuracy was Ϯ Ͻ10% and the mean precision was approximately 5% over the complete working range (proven by co-analysing appropriate QC samples produced by spiking blank plasma with known concentrations of the analytes). The lower limit of quantification (LOQ) was 2.5 g/L for the parent drug, 5 g/L for M1 and 40 g/L for M2.
Pharmacokinetic and statistical analysis
All pharmacokinetic evaluations were performed using non-compartmental methods. 10 Maximum plasma concentrations (C max ) and times to peak (t max ) were taken directly from the plasma concentration/time profiles. Terminal half-lives (t 1/2 ) were obtained by linear regression analysis of the last data points after log-transformation of the data. Areas under the curves extrapolated to infinity (AUC) were calculated using the log-linear trapezoidal rule. For all variables, descriptive statistics including mean values, standard deviations (S.D.), minimum, median and maximum values were applied. Explorative ANOVA to estimate absolute bioavailability as well as the withinsubject variation in AUC and C max was performed and 90% CI for the oral:iv AUC-and C max -ratios were calculated.
All parameters are presented as the geometric mean with geometric S.D. factor, with the exception of amounts excreted in urine and faeces where arithmetic means Ϯ S.D. are listed. For t max median and minimum-maximum ranges are given.
Absorption analysis
Absorption analyses of the plasma concentration vs time profiles were performed by deconvolution 11 of the individual profiles. The fraction absorbed (expressed as
Plasma protein binding
Plasma protein binding in the presence of different concentrations of the analytes was determined ex vivo by a membrane filtration method. Two pooled plasma samples from two subjects each were deproteinated by ultrafiltration centrifugation (1900g for at least 10 min) with the Centricon device (Centricon, Amicon, Switzerland). For the validation of the protein binding results standards produced from blank plasma spiked with known concentrations of moxifloxacin, M1 and M2 were used. Characterized standard moxifloxacin and M1 powders of known potency were provided by Bayer AG, Wuppertal, Germany. M2 was obtained by extraction from human urine and purification with methanol/water using a C18 chromabound cartridge (Macherey & Nagel, Düren, Germany). The solvent was quantitatively evaporated from the extract in a vacuum centrifuge (4 h, room temperature). Before its use for protein binding experiments, the purity of the metabolite was verified by HPLC (as described above) before and after enzymatic deglucuronidation.
Results
Safety
Moxifloxacin was well tolerated throughout the study. All volunteers completed both periods of the study. There were a few adverse events recorded for the subjects: all were mild in nature. One episode of abdominal pain was observed during the iv treatment. Four cases of headache were reported: two in each treatment group. One subject accidentally cut his finger during the study. Vital signs, ECG and standard biochemical and haematological parameters did not show any clinically relevant deviations from normal.
Protein binding
The data obtained for protein binding of the drug and the two metabolites are shown in Table I . In contrast to M2, where the unbound fraction (f u ) was у95%, M1 was highly bound to plasma proteins (f u Ϸ 10%). For all substances, the degree of protein binding was independent of the plasma concentration for the range of concentrations investigated.
Pharmacokinetics of moxifloxacin
The plasma concentration vs time profiles of both treatments are illustrated in Figure 2 . The non-compartmental pharmacokinetic parameters are summarized in Table II. Bioavailability of the drug is almost complete (86%). The statistical analysis reveals a low variability with even bioequivalence criteria (point estimate and 90% CI of the ratio oral:iv within 80-125%) met for AUC (86%, range 74-106%; 90% CI 81-91%). Peak concentrations were approximately 31% lower after oral administration of the drug, with a mean ratio for C max,po /C max,iv of 69% (range 51-94%; 90% CI 62-77%). This confirms that exposure to drug is equivalent for an oral and iv 400 mg dosages.
Absorption of the drug is described in Figure 3 . Drug uptake is fast with moderate variability. Eighty-six per cent of the drug is absorbed with a mean dissolution time of 2.4/1.45 h (geometric mean/S.D.). Figure 4a and b presents the excretion pattern (cumulative and fractional amounts excreted into urine in the subset of volunteers eligible for the mass balance) for both routes of administration. There were no significant differences in renal elimination. 
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Pharmacokinetics of metabolites
Plasma concentrations for M1 and M2 were determined in a subgroup of eight subjects. The plasma concentration vs time profiles of both treatments are illustrated in Figure  5 .
The terminal slope of the plasma concentration vs time curves of both metabolites followed those of the parent compound but, owing to the lower concentrations, were not detectable over the whole observation period of 96 h. It is apparent that exposure to M1 is lower in the plasma than exposure to M2, the mean concentrations of which were approximately 2.5-6 times higher. The pharmacokinetic characteristics of both metabolites are summarized in Table III .
Quantification of drug elimination
The results of the mass balance investigation undertaken in this study are illustrated in Table IV . No significant differences in excretion patterns were found between oral or iv administration.
Discussion
The results of this study confirm those of other trials investigating pharmacokinetics of moxifloxacin following oral and iv dosing. [12] [13] [14] [15] The bioavailability of moxifloxacin is almost complete and has a low variability as reported for other fluoroquinolones. [16] [17] [18] [19] The data demonstrate that a regimen of 400 mg od can be administered independently of the route of administration, since equivalent exposure in terms of AUC can be found. During iv treatment higher peak concentrations (approximately 31%) are achieved, compared with oral administration, which is consistent with an absolute bioavailability of approximately 86% and can be explained by the higher input rate during a 1 h infusion. The peak concentrations reached after oral and iv administration were far above the MICs for the susceptible micro- organisms (e.g. Streptococcus pneumoniae, MIC 90 0.12 mg/L) providing a comfortable safety margin to avoid emergence of resistance during antimicrobial therapy, assuming that C max /MIC is the indicative parameter. 20 The drug concentrations remained above the MIC 90 for more than 24 h after dosing. Hence, an od dosing regimen seems to provide an excellent safety margin for the treatment of respiratory tract infections in terms of antimicrobial activity. That the AUC and C max are similar after oral and iv administration suggests that the safety profiles for both regimens will be similar. The safety data obtained in this study support this.
The fast decline of the plasma concentrations after the end of infusion indicates a very rapid distribution of the drug. V ss was very high in agreement with previous reports. 15 The unbound fraction of approximately 60% (Table I ) determined in this study confirms other studies. 12 Moxifloxacin is cleared from the plasma with a terminal half-life of approximately 12 h. A total body clearance of 12 L/h suggests that moxifloxacin is a low clearance drug. Approximately 20% of the drug is excreted unchanged into urine. The mechanism of renal excretion can be interpreted as partial tubular reabsorption of the drug (CL R ϭ 43 mL/min), since the CL R of a drug with a protein binding of approximately 40% should be approximately 70 mL/min assuming excretion by glomerular filtration alone. The pharmacokinetics of M1 were very similar following oral and iv administration of moxifloxacin. Parameters related to disposition had a higher variability for iv administration compared with oral administration. Independent of the route of administration, the terminal slopes of the plasma M1 concentration vs time curves declined parallel to the corresponding curves for moxifloxacin. Hence, comparison of the half-lives does not reveal significant differences in pharmacokinetics related to distribution and elimination of M1 by whichever route of administration the parent drug is used.
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Excretion of M1 was also independent of the route of administration. The data for the (renal and total) clearance of the metabolite clearly indicate that M1 is a high clearance substance mainly excreted from the liver/bile into the faeces (Table IV) . Based on the high protein binding of the metabolite, the mechanism of renal excretion can be interpreted as net active tubular secretion, since the renal clearance of the compound (geometric mean Ϸ 195-218 mL/min) is far above 12 mL/min, the value expected for excretion by glomerular filtration.
M2 is the main metabolite observed in the plasma, with concentrations ranging between those of the parent drug (approximately five times smaller) and M1 (approximately three times higher). Following oral administration of the drug the mean concentrations of M2 were approximately twice as high as those reached following a 1 h infusion. Part of the drug entering the systemic circulation orally is cleared in the first pass through the liver and/or presystemically by glucuronidation.
Disposition of M2 was higher than for M1. Independent of the route of administration the terminal slopes of the plasma M2 concentration vs time curves declined parallel to the corresponding curves for moxifloxacin. As for M1, comparison of the parameters does not reveal significant administration-related differences in pharmacokinetics with respect to distribution and elimination of M2.
M2 is excreted via the kidneys by active tubular secretion. It cannot be found in the faeces (Table IV) .
Elimination pathways of moxifloxacin were quantitatively described in the study. The results confirmed previous findings suggesting that only phase 2 metabolism is relevant in man. 7 Furthermore, it was shown that the dose is quantitatively recovered from faeces and urine within approximately 6 days after treatment, proving that elimination is well balanced. Thus, the risk of critical drug accumulation in case of renal or hepatic impairment is minimized. This conclusion is confirmed by pharmacokinetic data on moxifloxacin in subjects with various degrees of renal impairment. 21 Since both metabolites formed are pharmacologically inactive (A. Dalhoff, personal communication, 1998) and their systemic exposure is far lower compared with the parent drug, their pharmacokinetic characteristics combined with the safety results in this and other studies [12] [13] [14] [15] suggest that moxifloxacin would be a safe and well tolerated agent to treat microbial infections.
